Statements (53)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:activities |
inhibits microtubule depolymerization
|
| gptkbp:appointed_by |
intravenous infusion
|
| gptkbp:approves |
gptkb:1996
gptkb:FDA |
| gptkbp:brand |
gptkb:docetaxel
|
| gptkbp:can_be_used_with |
gptkb:cisplatin
gptkb:carboplatin gptkb:doxorubicin |
| gptkbp:class |
gptkb:taxanes
|
| gptkbp:clinical_trial |
combination therapy
Phase III monotherapy |
| gptkbp:contraindication |
severe liver impairment
neutrophil count less than 1500/mm³ |
| gptkbp:excretion |
bile
|
| gptkbp:formulation |
concentrate for solution for infusion
|
| https://www.w3.org/2000/01/rdf-schema#label |
Taxotere
|
| gptkbp:indication |
gptkb:healthcare_organization
ovarian cancer esophageal cancer bladder cancer head and neck cancer neuroendocrine tumors gastric adenocarcinoma |
| gptkbp:ingredients |
gptkb:docetaxel
C43 H53 N3 O14 S |
| gptkbp:interacts_with |
CY P3 A4 inducers
CY P3 A4 inhibitors |
| gptkbp:is_atype_of |
L01 C D02
|
| gptkbp:is_monitored_by |
liver function tests
blood counts |
| gptkbp:is_used_for |
treating breast cancer
treating prostate cancer treating lung cancer |
| gptkbp:lifespan |
35 hours
|
| gptkbp:manager |
IV
|
| gptkbp:manufacturer |
gptkb:Sanofi
|
| gptkbp:packaging |
vial
|
| gptkbp:pharmacokinetics |
highly protein-bound
|
| gptkbp:safety_features |
risk of infection
risk of bleeding risk of severe allergic reactions risk of fluid retention |
| gptkbp:side_effect |
fatigue
nausea hair loss low blood cell counts |
| gptkbp:storage |
room temperature
|
| gptkbp:type_of |
114977-28-5
|
| gptkbp:weight |
807.95 g/mol
|
| gptkbp:bfsParent |
gptkb:docetaxel
|
| gptkbp:bfsLayer |
5
|